ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5 | -37.5% | 200 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $8 | +33.3% | 200 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $6 | 0.0% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $6 | -99.9% | 200 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $7,000 | -12.5% | 200 | 0.0% | 0.00% | -50.0% |
| Q2 2022 | $8,000 | -11.1% | 200 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $9,000 | -30.8% | 200 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $13,000 | +8.3% | 200 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $12,000 | -58.6% | 200 | -42.9% | 0.00% | -60.0% |
| Q2 2021 | $29,000 | +26.1% | 350 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $23,000 | -57.4% | 350 | -50.0% | 0.00% | -63.6% |
| Q4 2020 | $54,000 | +80.0% | 700 | 0.0% | 0.01% | +57.1% |
| Q3 2020 | $30,000 | 0.0% | 700 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $30,000 | +50.0% | 700 | 0.0% | 0.01% | +16.7% |
| Q1 2020 | $20,000 | -68.3% | 700 | -30.0% | 0.01% | -62.5% |
| Q4 2019 | $63,000 | +125.0% | 1,000 | 0.0% | 0.02% | +100.0% |
| Q3 2019 | $28,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |